CSIMarket Company Name, Ticker, Competitors, else..


Lexaria Bioscience Corp   (NASDAQ: LEXX)
Other Ticker:  
 


 

Lexaria Bioscience Corp

LEXX's Financial Statements and Analysis



Lexaria Bioscience Corp increased second quarter of 2025 net loss per share of $-0.15 compare to net loss per share of $-0.06 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.16 realized in previous quarter.


second quarter of 2025
Earnings Per Share Revenues
$ -0.15 $  0 Mill
$-0.09     Unch.     +20 %



Lexaria Bioscience 's Revenue rose by 20 % in second quarter of 2025 (Feb 28 2025) year on year, to $0 million and declined by -5.4 % sequentially.


Lexaria Bioscience is

More on LEXX's Income Statement



Lexaria Bioscience in the second quarter of 2025 recorded net loss of $-2.717 million, an increase from net loss of $-0.653 million in II. Quarter a year ago.

Sequentially net loss advanced

More on LEXX's Growth

Lexaria Bioscience Inventories
In Feb 28 2025 company's net cash and cash equivalents decreased by $-2 million, capital expenditures grew by -0.05699-100.00%, to $0 millions compare to same quarter a year ago

More on LEXX's Cash flow Statement


Lexaria Bioscience Corp does not pay out common stock dividend.

In trailing twelve-month period Lexaria Bioscience Corp payed $ -0.42 cash per share, on a free-cash flow basis .

Book value fell by -31.50 % sequentially to $0.39 per share, -33.25% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.36 per share from $ 0.53.

Company issued 0.84 million shares or 5.06 % in Feb 28 2025.


• More on LEXX's Dividends

 Market Capitalization (Millions) 25
 Shares Outstanding (Millions) 18
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 27




Lexaria Bioscience Corp does not pay out common stock dividend.

In trailing twelve-month period Lexaria Bioscience Corp had negative $ -0.42 cash flow per share, on a free-cash flow basis .

Book value fell by -31.50 % sequentially to $0.39 per share, -33.25% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.36 per share from $ 0.53.

Company issued 0.84 million shares or 5.06 % in Feb 28 2025.


• More on LEXX's Balance Sheets

 Market Capitalization (Millions) 25
 Shares Outstanding (Millions) 18
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 27
   


  News about Lexaria Bioscience Corp Earnings

Lexaria Bioscience Corp's Innovative Drug-Delivery System Shines in Second Quarter of 2024 Efforts

Lexaria Bioscience Corp has been making waves in the pharmaceutical industry with its groundbreaking drug-delivery system that has the potential to revolutionize medical treatments. This innovative technology has shown promise in improving the way molecules enter the bloodstream, offering new possibilities for GLP-1 Diabetes and weight-loss drugs.
In the second quarter of 2024 earnings season, the company reported a significant improvement in its financial performance. The loss per share decreased to $-0.06 from $-0.22 a year before, while the revenue grew sharply by 314.108% to $0.15 million. The net loss also narrowed to $-0.653 million from $-1.311 million in the corresponding reporting period a year...

Lexaria Bioscience Corp's Game-Changing Drug-Delivery System Unveiled, Unlocking the Future of Medical Treatments

Lexaria Bioscience Corp (NASDAQ: LEXX) has recently unveiled its groundbreaking proprietary drug-delivery system, signaling a potential revolution in medical treatments. This innovative technology offers new possibilities for GLP-1 Diabetes and weight-loss drugs, presenting a solution to some of the most significant challenges in the pharmaceutical industry. While the company reported a cumulative net loss of $-8 million in the fourth quarter of 2023, its drug-delivery system holds promise for long-term success.
Lexaria's drug-delivery system has the potential to transform the way molecules enter the bloodstream, offering an exciting avenue for revolutionary cures. By addressing the challenges faced by t...

Vanishing Deficit: Lexaria Bioscience Corp's Remarkable Financial Turnaround Signals a Promising Future 2.

Lexaria Bioscience Corp, a renowned pharmaceutical company, has recently showcased a significant improvement in its financial performance. In the most recent fiscal period, the company successfully reduced its loss per share to $-0.12 per share, a notable improvement compared to $-0.25 per share in the same period last year. This positive development highlights the company's efforts in enhancing its profitability and financial stability.
Moreover, Lexaria Bioscience Corp's performance in the preceding financial reporting period was even more impressive. In this period, the company reported a loss per share of $-0.37, which demonstrates a substantial decrease from their previous financial reporting period...

Lexaria Bioscience Corp Reports Increased Deficit Per Share and Decrease in Revenue for Q3 2023


Introduction:
Lexaria Bioscience Corp, a pioneering biotechnology company specializing in innovative drug delivery platforms, recently released its financial results for the fiscal interval ending May 31, 2023. The company experienced an increase in its deficit per share and a decline in revenue, raising concerns amongst investors. However, encouraging trends in the company's stock performance suggest potential for future growth.
Fiscal Performance:
For the fiscal period ending May 31, 2023, Lexaria Bioscience Corp reported a deficit per share of $-0.37, indicating a decline compared to $0.00 per share from the previous year. Moreover, this represents a widening deficit from $-0.22 per share...


Date modified: 2025-04-15T17:25:10+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com